ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy

A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge's ELP Platform (Elastin...

Sarepta Reiterated Total Net Product Revenue of $3.0 Billion in 2025

As children and families battling Duchenne Muscular Dystrophy wait for drug prices to drop, Sarepta has announced its earnings...

Wave Life Sciences Announces Plans for Exon 53 Skipping Study in 2025

Alpha-1 antitrypsin deficiency (AATD), Huntington's disease (HD), obesity, and Duchenne muscular dystrophy (DMD) are among the major unmet medical...